| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5729695 | European Urology Focus | 2016 | 7 Pages |
Abstract
Combinations of immunotherapy with angiogenesis inhibitors are undergoing vigorous clinical trial evaluations. Sequencing of immunotherapy and antiangiogenic therapy is also undergoing investigation. Clinical trial participation is critically important to develop new drugs and combinations, and biomarkers to select therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Grant D. Stewart, Maria De Santis, Bernard Escudier, Thomas Powles, Guru Sonpavde,